Keira P. Mason
Boston Children's Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Keira P. Mason.
Journal of Vascular and Interventional Radiology | 2004
Patricia E. Burrows; Keira P. Mason
Low flow vascular malformations, especially venous and macrocystic lymphatic malformations, are effectively treated by percutaneous intralesional injection of sclerosant drugs, such as ethanol and detergent sclerosant drugs. Good to excellent results are possible in 75%-90% of patients who undergo serial sclerotherapy. Most adverse effects are manageable, but severe complications can result from the intravascular administration of ethanol. It is generally recommended that the treatment of vascular malformations be performed in a multidisciplinary setting by practitioners with appropriate training and support.
Pediatric Anesthesia | 2008
Keira P. Mason; David Zurakowski; Steven E. Zgleszewski; Caroline D. Robson; Maureen Carrier; Paul R. Hickey; James A. DiNardo
Objective: This large‐scale retrospective review evaluates the sedation profile of dexmedetomidine.
Anesthesia & Analgesia | 2006
Keira P. Mason; Steven E. Zgleszewski; Jennifer L. Dearden; Raymond S. Dumont; Michele A. Pirich; Cynthia Stark; Peggy D'angelo; Shann Macpherson; Paulette J. Fontaine; Linda Connor; David Zurakowski
Dexmedetomidine is a sedative with limited experience in the pediatric population. This is the first study that prospectively evaluates the sedation profile of a dexmedetomidine pilot program for pediatric sedation for radiological imaging studies. In March 2005, our hospital sedation committee approved the replacement of IV pentobarbital with dexmedetomidine as the standard of care for CT imaging. Detailed Quality Assurance (QA) data sheets collect relevant information on each patient, which is then logged into a computerized sedation database. After IRB approval, all QA data was accessed. Sixty-two patients with a mean age of 2.8 years (SD = 1.8, range 0.5–9.7) received IV (IV) dexmedetomidine administered as a 2 mcg/kg loading dose over 10 minutes, followed by repeat boluses of 2 mcg/kg over 10 minutes until target of Ramsay Sedation Score 4 (RSS) achieved. Patients were then maintained on 1 mcg/kg/hr infusion until imaging is completed. Repeated-measures ANOVA indicated that compared to pre-sedation values, the heart rate and mean arterial blood pressure decreased an average of 15% during bolus, infusion and recovery (P < 0.01). No significant changes were observed in respiratory rate or end-tidal CO2. Mean recovery time was 32 ± 18 minutes. Based on our pilot results, dexmedetomidine may provide a reliable and effective method of providing sedation.
Anesthesia & Analgesia | 2011
Keira P. Mason; Jerrold Lerman
More than 200 studies and reports have been published regarding the use of dexmedetomidine in infants and children. We reviewed the English literature to summarize the current state of knowledge of this drug in children for the practicing anesthesiologist. Dexmedetomidine is an effective sedative for infants and children that only minimally depresses the respiratory system while maintaining a patent airway. However, dexmedetomidine does depress the cardiovascular system. Specifically, bradycardia, hypotension, and hypertension occur to varying degrees depending on the age of the child. Hypertension is more prevalent when larger doses of dexmedetomidine are given to infants. Consistent with its 2-hour elimination half-life, recovery after dexmedetomidine may be protracted in comparison with other sedatives. Dexmedetomidine provides and augments analgesia and diminishes shivering as well as agitation postoperatively. The safety record of dexmedetomidine suggests that it can be used effectively and safely in children, with appropriate monitoring and interventions to manage cardiovascular sequelae.
Pediatric Anesthesia | 2009
Keira P. Mason; Elizabeth O’Mahony; David Zurakowski; Mark H. Libenson
Objectives: To examine the effects of dexmedetomidine sedation on EEG background and epileptiform activity in children, comparing it to natural sleep.
Pediatric Anesthesia | 2008
Keira P. Mason; Steven E. Zgleszewski; Randy Prescilla; Paulette J. Fontaine; David Zurakowski
Background: Dexmedetomidine sedation for radiological imaging studies is a relatively recent application for this drug. Previous studies have demonstrated some haemodynamic effects of dexmedetomidine, however, the effects remain poorly described in children. The aim of this study was to better define the effect of age on heart rate (HR) and blood pressure changes in children sedated for CT imaging with dexmedetomidine.
BJA: British Journal of Anaesthesia | 2012
Keira P. Mason; Steven M. Green; Q. Piacevoli
Currently, there are no established definitions or terminology for sedation-related adverse events (AEs). With clear terminology and definitions, sedation events may be accurately identified and tracked, providing a benchmark for defining the occurrence of AEs, ranging from minimal to severe. This terminology could apply to sedation performed in any location and by any provider. We present a consensus document from the International Sedation Task Force (ISTF) of the World Society of Intravenous Anaesthesia (World SIVA). The ISTF is composed of adult and paediatric sedation practitioners from multiple disciplines throughout the world.
BJA: British Journal of Anaesthesia | 2015
Mohamed Mahmoud; Keira P. Mason
Despite lack of paediatric labelling, contributions to the literature on paediatric applications of dexmedetomidine have increased over recent years. Dexmedetomidine possesses many properties that are advantageous for a sedative and anaesthetic; it has been reported to provide sedation that parallels natural sleep, anxiolysis, analgesia, sympatholysis, and an anaesthetic-sparing effect with minimal respiratory depression. In addition, there is increasing evidence supporting its organ-protective effects against ischaemic and hypoxic injury. These favourable physiological effects combined with a limited adverse effect profile make dexmedetomidine an attractive adjunct to anaesthesia (general and regional) for a variety of procedures in paediatric operating rooms. A comprehensive understanding of the pharmacological, pharmacokinetic, and pharmacodynamic effects of dexmedetomidine is critical to maximize its safe, efficacious, and efficient paediatric perioperative applications. This review focuses on the current paediatric perioperative and periprocedural applications of dexmedetomidine and its limitations, with a consideration for the future.
Pediatric Anesthesia | 2010
Keira P. Mason; David Zurakowski; Steven E. Zgleszewski; Randy Prescilla; Paulette J. Fontaine; James A. DiNardo
This study reviewed the hypertensive response of a large population of children to high‐dose dexmedetomidine sedation with the aim of determining the incidence and predictors of hypertension.
Journal of Clinical Monitoring and Computing | 2000
Keira P. Mason; Patricia E. Burrows; Maureen M. Dorsey; David Zurakowski; Baruch Krauss
We tested the accuracy of a low flow (50 cc/min) sidestream capnographysystem equipped with an experimental 30-foot nasal cannula to monitor ventilatory status in children. End-tidal CO2 and respiratory rate, both at room air and in the presence of supplemental oxygen, were recorded simultaneously from the experimental 30-foot nasal cannula and the standard, FDA approved, 10-foot nasal cannula. The 30-foot nasal cannula was as accurate as the 10-foot nasal cannula in measuring respiratory rate and end-tidal CO2 in children. When supplemental oxygen was delivered by facemask, there was no dilutional effect on the respiratory rate or end-tidal CO2 recorded with either the 10-foot or 30-foot nasal cannulas inplace.